Sphingolipids in Cancer - 1st Edition - ISBN: 9780128142233, 9780128142240

Sphingolipids in Cancer, Volume 140

1st Edition

Serial Volume Editors: Charles E. Chalfant Paul Fisher
eBook ISBN: 9780128142240
Hardcover ISBN: 9780128142233
Imprint: Academic Press
Published Date: 31st July 2018
Page Count: 410
Sales tax will be calculated at check-out Price includes VAT/GST
239.04
203.18
171.00
145.35
122.00
103.70
119.00
101.15
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Mechanisms of ceramide-dependent cancer cell death
  2. Rose Nganga, Natalia Oleinik and Besim Ogretmen

  3. Sphingolipids as regulators of autophagy and endocytic trafficking
  4. Megan M. Young and Hong-Gang Wang

  5. Role and function of sphingomyelin biosynthesis in the development of cancer
  6. Giovanni D’Angelo, Sitapriya Moorthi and Chiara Luberto

  7. Neutral sphingomyelinases in cancer: friend or foe?
  8. Christopher J. Clarke

  9. Ceramide and exosomes: a novel target in cancer biology and therapy
  10. Ahmed Elsherbini and Erhard Bieberich

  11. Sphingolipids at the crossroads of NAFLD and senescence
  12. Mariana Nikolova-Karakashian

  13. Ceramide signaling and p53 pathways
  14. Kristen Jeffries and Natalia Krupenko

  15. The role of ceramide 1-phosphate in tumor cell survival and dissemination
  16. Antonio Gomez-Muñoz

  17. The onus of sphingolipid enzymes in cancer drug resistance
  18. Samy A.F. Morad and Myles C. Cabot

  19. Interdiction of sphingolipid metabolism revisited: focus on prostate cancer
  20. Christina Voelkel-Johnson, James S. Norris and Shai White-Gilbertson

  21. Targeting sphingosine kinases for the treatment of cancer
  22. Clayton S. Lewis, Christina Voelkel-Johnson and Charles D. Smith

  23. Novel sphingolipid-based cancer therapeutics in the personalized medicine era
  24. Jeremy Shaw, Pedro Costa-Pinheiro, Logan Patterson, Kelly Drews, Sarah Spiegel and Mark Kester

  25. Side effects in cancer therapy: are sphingolipids to blame?

Falak Patel and Stefka D. Spassieva


Description

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

Key Features

  • Provides information on cancer research, with this release focusing on sphingolipids
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


Details

No. of pages:
410
Language:
English
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
eBook ISBN:
9780128142240
Hardcover ISBN:
9780128142233

Ratings and Reviews


About the Serial Volume Editors

Charles E. Chalfant Serial Volume Editor

Professor Charles E. Chalfant heads up the Chalfant Laboratory and is the director of the Lipidomic Facility at Virgina Commonwealth University. The Chalfant laboratory is currently focused on two major areas of cell signaling and human pathophysiologies: 1) lipid and oncogenic regulation of alternative splicing; and 2) the regulation of eicosanoid synthesis in inflammation and cancer.

Affiliations and Expertise

Director of Lipidomics Facility, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

Paul Fisher

Paul Fisher Serial Volume Editor

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 600 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA